Anti-CD3 Recombinant Diphtheria Immunotoxin Therapy of Cutaneous T Cell Lymphoma

E-ISSN： 1873-5592|10|2|104-109

ISSN： 1389-4501

Source： Current Drug Targets, Vol.10, Iss.2, 2009-02, pp. : 104-109

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Frequent expression of CD30 in extranodal NK/T‐cell lymphoma: Potential therapeutic target for anti‐CD30 antibody‐based therapy

Hematological Oncology (Electronic), Vol. 36, Iss. 1, 2018-02 ,pp. : 166-173

John Wiley & Sons Inc

Access to resources Recommend Favorite

Management of cutaneous T-cell lymphoma

By Duhovic Chris Child Fiona Wain E Mary

Clinical Medicine, Vol. 12, Iss. 2, 2012-04 ,pp. : 160-164

Royal College Of Physicians

Access to resources Recommend Favorite

Efalizumab/infliximab: CD8+ cutaneous T cell lymphoma (first report with efalizumab): 2 case reports

Reactions Weekly, Vol. 1, Iss. 1137, 2007-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Interferon (IFN)- plus bexarotene were effective in the treatment of multi focal, cutaneous, CD30+, large T cell lymphoma

Inpharma, Vol. 1, Iss. 1324, 2002-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Emerging drugs in cutaneous T cell lymphoma

By Mestel Dominik Sebastian Assaf Chalid Steinhoff Matthias Beyer Marc Moebs Markus Sterry Wolfram

Expert Opinion on Emerging Drugs, Vol. 13, Iss. 2, 2008-06 ,pp. : 345-361

Informa Healthcare

Access to resources Recommend Favorite